Bachem Holding AG

Swiss Stock Exchange BANB.SW

Bachem Holding AG Return on Equity (ROE) for the year ending December 31, 2023: 8.47%

Bachem Holding AG Return on Equity (ROE) is 8.47% for the year ending December 31, 2023, a -1.59% change year over year. Return on equity measures profit against shareholder equity; higher ROE indicates superior profitability and value creation.

Bachem Holding AG Return on Equity (ROE) for the year ending December 31, 2022 was 8.61%, a -15.86% change year over year.
Bachem Holding AG Return on Equity (ROE) for the year ending December 31, 2021 was 10.23%, a -37.66% change year over year.
Bachem Holding AG Return on Equity (ROE) for the year ending December 31, 2020 was 16.41%, a 35.67% change year over year.
Bachem Holding AG Return on Equity (ROE) for the year ending December 31, 2019 was 12.10%, a -0.37% change year over year.

Key data

Date	Return on Equity (ROE)	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio

Swiss Stock Exchange: BANB.SW

Bachem Holding AG

CEO	Mr. Thomas Meier
IPO Date	July 17, 1998
Location	Switzerland
Headquarters	Hauptstrasse 144
Employees	2,009
Sector	Health Care
Industries Pharmaceuticals Biotechnology Chemicals & Advanced Materials

Description

Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.

Key trends

Past 5 years